Johnson & Johnson Profit Margin 2006-2020 | JNJ

Current and historical gross margin, operating margin and net profit margin for Johnson & Johnson (JNJ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Johnson & Johnson net profit margin as of December 31, 2020 is 17.82%.
Johnson & Johnson Annual Profit Margins
Johnson & Johnson Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $416.541B $82.584B
Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin care, oral care, wound care, and women's health fields, nutritional and over-the-counter pharmaceutical products. The company's Pharmaceutical segment provides various products in the areas of anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, thrombosis, vaccines, and infectious diseases. Its Medical Devices and Diagnostics segment offers electrophysiology and circulatory disease management products; orthopaedic joint reconstruction, spinal care, neurological, and sports medicine products; surgical care, aesthetics, and women's health products. Johnson & Johnson is based in New Brunswick, New Jersey.
Stock Name Country Market Cap PE Ratio
Roche Holding AG (RHHBY) Switzerland $281.473B 0.00
Novartis AG (NVS) Switzerland $196.622B 14.91
Eli Lilly (LLY) United States $196.372B 25.84
AbbVie (ABBV) United States $190.256B 10.25
Pfizer (PFE) United States $186.151B 12.31
Merck (MRK) United States $183.731B 12.25
Novo Nordisk (NVO) Denmark $167.780B 25.91
AstraZeneca (AZN) United Kingdom $126.978B 23.95
Sanofi (SNY) $115.548B 13.70
GlaxoSmithKline (GSK) United Kingdom $84.311B 11.24
H Lundbeck (HLUYY) Denmark $7.639B 13.51
Innoviva (INVA) United States $1.159B 5.15